Edoxaban is a once-daily oral factor Xa (FXa) inhibitor that is noninferior to well-managed warfarin for the prevention of stroke or SEE in patients with AF and a CHADS2 score ≥2.12 In addition to preventing thromboembolic events, edoxaban significantly reduced the risk of bleeding and cardiovascular death in comparison with warfarin. Here, F10 is linked to atrial fibrillation.